Tissue and extracellular matrix remodelling in pulmonary fibrosis and chronic lung allograft dysfunction
In recent years, the prevalence of idiopathic pulmonary fibrosis (IPF) and post-COVID-19 pulmonary fibrosis has risen. Nevertheless, effective diagnostic and prognostic biomarkers alongside targeted treatments are lacking, making lung transplantation the last resort for many patients with end-stage disease. However, bronchiolitis obliterans syndrome (BOS), a manifestation of chronic lung allograft
